Aug. 6 at 5:29 PM
$RNXT is a rare ~
$50M biotech/medtech with BOTH real commercial revenue and a pivotal oncology catalyst.
Q1 RenovoCath revenue:
$563K, +136% QoQ. Active cancer centers grew from 5 at the start of 2025 to 16 by May, with 32 more in evaluation/onboarding. Cash:
$12.4M; runway guided into H2 2027.
TIGeR-PaC is randomized Phase III in locally advanced pancreatic cancer: 106 patients randomized, 74/86 required OS events, and the IDMC recommended continuing. Final data expected in 2027.
$5-
$6 implies roughly a
$225M-
$270M basic market cap. Plausible only if RNXT proves repeat orders, completes enrollment, scales centers/revenue and delivers a meaningful OS benefit. Warrants/dilution are the main risks.
Not comparing size, but the rerating mechanics are familiar to investors in
$LXRX $BMY $JNJ $MDT: platform validation + commercial traction + pivotal success.
Bull path:
$1.25-
$1.50 on execution, 2+ on acceleration,
$5-
$6 on validated-platform status. #biotech #oncology
